http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8899289

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article
endingPage 917
issn 1532-1827
0007-0920
issueIdentifier 6
pageRange 912-917
publicationName British Journal of Cancer
startingPage 912
bibliographicCitation Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kähler G, Post S, Hofheinz R. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. British Journal of Cancer. 2007 Feb 27;96(6):912–7. doi: 10.1038/sj.bjc.6603645.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc5a7f7fe30cc48a6eb63396810706e8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45f3e3e556c646cc60a03bcd441c4dcd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2eea788aa83238365bf9edb6d6527a76
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f96802eed00df9a65f7b67068ac89b7d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38f6c3c22ac45d679bc9cb0eaf6229ec
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b68ddc291e306f8bb21fb5f3907a314a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16a3425bf1c5a849e6d56fb2f0e42794
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2f09f995c471b6300fe9bdfba59fc49
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_84e185c3aaeb6bf59c1e5b8db869e1e9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc4c864c1d5cf7c7a1e19c012639563d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e3b329ff07fc93ddf7624f45da1490f
date 2007-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1038/sj.bjc.6603645
https://pubmed.ncbi.nlm.nih.gov/17325705
https://pubmed.ncbi.nlm.nih.gov/PMC2360100
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
https://portal.issn.org/resource/ISSN/1532-1827
https://portal.issn.org/resource/ISSN/0007-0920
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
discusses http://id.nlm.nih.gov/mesh/M0008631
http://id.nlm.nih.gov/mesh/M0005997
http://id.nlm.nih.gov/mesh/M0147530
http://id.nlm.nih.gov/mesh/M0287377
http://id.nlm.nih.gov/mesh/M0003242
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112
http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103
http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10251
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9060
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11650937
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9591
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136058681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127385558
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127925204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129735276
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129281950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129623383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853

Total number of triples: 66.